You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

na
Coming soon

Sorry, we are still working on this page.
Be the first to find out about new content by signing up with GSKpro.

Request a contact

If you'd like one of our Key Account Managers or Medical Advisors to contact you, please click on the link and fill out the form.

Shingrix▼ is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in adults 50 years of age or older and adult 18 years of age or older at increased risk of HZ.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Preparation: February 2022 PM-IE-SGX-WCNT-210008